BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1503 related articles for article (PubMed ID: 22395978)

  • 1. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
    Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
    Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to neoadjuvant therapy in locally advanced rectal cancer: assessment with diffusion-weighted MR imaging and 18FDG PET/CT.
    Ippolito D; Monguzzi L; Guerra L; Deponti E; Gardani G; Messa C; Sironi S
    Abdom Imaging; 2012 Dec; 37(6):1032-40. PubMed ID: 22270580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
    Kim CW; Yu CS; Yang SS; Kim KH; Yoon YS; Yoon SN; Lim SB; Kim JC
    Ann Surg Oncol; 2011 Nov; 18(12):3271-7. PubMed ID: 21537868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
    Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
    Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Chennupati SK; Quon A; Kamaya A; Pai RK; La T; Krakow TE; Graves E; Koong AC; Chang DT
    Am J Clin Oncol; 2012 Aug; 35(4):334-9. PubMed ID: 21422989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation.
    Sorenson E; Lambreton F; Yu JQ; Li T; Denlinger CS; Meyer JE; Sigurdson ER; Farma JM
    J Surg Res; 2019 Nov; 243():242-248. PubMed ID: 31229791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
    Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
    Leibold T; Akhurst TJ; Chessin DB; Yeung HW; Macapinlac H; Shia J; Minsky BD; Saltz LB; Riedel E; Mazumdar M; Paty PB; Weiser MR; Wong WD; Larson SM; Guillem JG
    Ann Surg Oncol; 2011 Oct; 18(10):2783-9. PubMed ID: 21476107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
    Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
    Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
    Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficiency of
    Uemura M; Ikeda M; Handa R; Danno K; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Doki Y; Eguchi H
    BMC Cancer; 2021 Oct; 21(1):1132. PubMed ID: 34674666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis.
    Shin US; Yu CS; Kim JH; Kim TW; Lim SB; Yoon SN; Yoon YS; Kim CW; Kim JC
    Ann Surg Oncol; 2011 Aug; 18(8):2232-9. PubMed ID: 21347780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.